- Home
- UHS vs EXEL Comparison
UHS vs EXEL Comparison
Compare UHS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHS
- EXEL
- Stock Information
- Founded
- UHS 1978
- EXEL 1994
- Country
- UHS United States
- EXEL United States
- Employees
- UHS N/A
- EXEL N/A
- Industry
- UHS Hospital/Nursing Management
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UHS Health Care
- EXEL Health Care
- Exchange
- UHS Nasdaq
- EXEL Nasdaq
- Market Cap
- UHS 13.4B
- EXEL 10.4B
- IPO Year
- UHS N/A
- EXEL 2000
- Fundamental
- Price
- UHS $222.71
- EXEL $40.99
- Analyst Decision
- UHS Buy
- EXEL Buy
- Analyst Count
- UHS 13
- EXEL 24
- Target Price
- UHS $231.62
- EXEL $44.73
- AVG Volume (30 Days)
- UHS 640.5K
- EXEL 3.2M
- Earning Date
- UHS 10-27-2025
- EXEL 11-04-2025
- Dividend Yield
- UHS 0.36%
- EXEL N/A
- EPS Growth
- UHS 39.76
- EXEL 53.55
- EPS
- UHS 21.01
- EXEL 2.38
- Revenue
- UHS $16,992,503,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- UHS $10.41
- EXEL $9.14
- Revenue Next Year
- UHS $4.93
- EXEL $12.51
- P/E Ratio
- UHS $10.60
- EXEL $17.42
- Revenue Growth
- UHS 10.21
- EXEL 9.93
- 52 Week Low
- UHS $152.33
- EXEL $31.90
- 52 Week High
- UHS $229.76
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- UHS 61.40
- EXEL 59.59
- Support Level
- UHS $215.64
- EXEL $36.00
- Resistance Level
- UHS $229.76
- EXEL $41.55
- Average True Range (ATR)
- UHS 7.00
- EXEL 1.40
- MACD
- UHS 0.48
- EXEL 0.32
- Stochastic Oscillator
- UHS 75.89
- EXEL 91.61
About UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.